GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Revelation Biosciences
Revelation Biosciences is a biotech company developing drugs for the prevention and treatment of respiratory viral infections. Its stock price is highly volatile and reflects binary risks, as the company's entire value depends on the success or failure of its clinical trials, not on current revenue.
Share prices of companies in the market segment - Pharma immune
Revelation Biosciences is a biopharmaceutical company developing drugs for the prevention and treatment of diseases related to immune system function. We have classified the company in the Pharma: Immunology category. The chart below shows how the market is evaluating new approaches in immunology.
Broad Market Index - GURU.Markets
Revelation Biosciences is a biopharmaceutical company developing drugs to prevent and treat viral infections. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
REVB - Daily change in the company's share price Revelation Biosciences
Revelation Biosciences' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the clinical trials of its immunotherapy drugs.
Daily change in the price of a set of shares in a market segment - Pharma immune
Revelation Biosciences develops drugs to prevent and treat viral respiratory diseases. This biotech segment has become extremely volatile since the pandemic. The chart below shows the average fluctuations in this industry, providing context for REVB stock valuation.
Daily change in the price of a broad market stock, index - GURU.Markets
Revelation Biosciences is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Revelation Biosciences
Revelation Biosciences' year-over-year performance is a story of its search for a new path. Its market cap change over the past 12 months reflects its strategic pivot and search for new assets to acquire or merge following the failure of its previous clinical programs. Its valuation is essentially a reflection of its cash value and the belief that management will make the right move.
Annual dynamics of market capitalization of the market segment - Pharma immune
As an early-stage biotech company, Revelation is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its drugs. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Revelation Biosciences is a biotech company whose stock performance is entirely dependent on clinical trial results. A comparison with the market clearly demonstrates that its investors are focusing not on the Fed's interest rate but on lab news. Its path is a series of binary events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Revelation Biosciences
Revelation is a clinical-stage biopharmaceutical company. Its monthly performance is entirely dependent on the results of its clinical trials. News about its infectious and allergic disease programs are binary events.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Immunology is a field of biotech where companies are constantly searching for new treatment approaches. The dynamics of this sector, shown in the graph, reflect its high research intensity and risk. In this environment, companies like Revelation Biosciences are developing their pipeline.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Revelation Biosciences is an early-stage biotech company. Its shares are steeped in lab data and investor expectations for science. Their value can fluctuate wildly, ignoring macroeconomic events and broader market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Revelation Biosciences
Shares of Revelation Biosciences, a clinical-stage biopharmaceutical company, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials of their drugs for the treatment of viral and allergic diseases. The chart below illustrates how short-term scientific events can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Revelation Biosciences is an early-stage biotech company. Like many of its peers, it doesn't have stable revenue, and its shares fluctuate based on research progress. The chart clearly demonstrates the "binary" nature of such investments: their performance is completely unrelated to overall healthcare trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Revelation Biosciences is a biotech company focused on immunology. This chart shows how out of sync its weekly performance is with the broader market. Its stock price is driven by news about clinical trials and scientific progress, not the overall economic situation.
Market capitalization of the company, segment and market as a whole
REVB - Market capitalization of the company Revelation Biosciences
Revelation Biosciences' valuation chart tells the story of a biotech company finding its way after clinical trial failures. Its current market cap reflects not so much the value of its developments as its cash balance and speculative hopes that the company will find a promising new direction.
REVB - Share of the company's market capitalization Revelation Biosciences within the market segment - Pharma immune
Revelation Biosciences's stake in the immunology sector is based on its platform for stimulating innate immunity. Its market share is based on the potential of its developments for the prevention and treatment of respiratory viral infections, a highly relevant area.
Market capitalization of the market segment - Pharma immune
This chart shows the total market capitalization of biotech companies working in immunology and inflammatory diseases. Revelation Biosciences is one of the players in this field. The dynamics on the chart reflect the high risks and expectations associated with developing new drugs in this complex field.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's the market valuation of a biotech company focused on preventing viral infections. Revelation Biosciences' market cap reflects investors' faith in its nasal spray for stimulating innate immunity. The line shows how preventative medicine is trying to carve out a niche in the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
REVB - Book value capitalization of the company Revelation Biosciences
The graph below shows Revelation Biosciences' scientific foundation. Its line reflects the value of intellectual property for drugs stimulating innate immunity, as well as cash reserves for clinical trials. An increase in the graph indicates progress in research, which is the company's main asset.
REVB - Share of the company's book capitalization Revelation Biosciences within the market segment - Pharma immune
Revelation Biosciences' tangible assets are its R&D centers and laboratories, focused on developing immune system drugs. The chart shows the company's share of this scientific infrastructure, which serves as the physical base for its research into infection prevention and treatment.
Market segment balance sheet capitalization - Pharma immune
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Revelation Biosciences, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Revelation Biosciences develops therapeutics for the prevention and treatment of immune system-related diseases. Its assets include scientific research and clinical trial data. The chart shows the resources dedicated to "training" our immune system.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Revelation Biosciences
Revelation Biosciences is a clinical-stage biopharmaceutical company. Its market value is derived from its research in immunology. Investors are betting on its potential for treating and preventing viral diseases.
Market to book capitalization ratio in a market segment - Pharma immune
Revelation Biosciences is a biotech company developing drugs to treat and prevent respiratory viral infections. Its value depends on the success of its clinical programs. This chart clearly shows how its market valuation is a bet on future drugs and is significantly out of touch with its current assets.
Market to book capitalization ratio for the market as a whole
Revelation Biosciences develops immune-based drugs for the prevention and treatment of diseases. The company's market valuation, as shown in this chart, depends almost entirely on the prospects of its scientific developments. The dynamics reflect investors' optimism or skepticism regarding the results of upcoming clinical trials.
Debts of the company, segment and market as a whole
REVB - Company debts Revelation Biosciences
Revelation Biosciences, an early-stage biotech company, uses raised capital to fund its preclinical research in immunology. This chart shows how the company spends investor funds to test its scientific hypotheses, the first and riskiest step toward developing a new drug.
Market segment debts - Pharma immune
Revelation Biosciences is an early-stage biotech company researching drugs for the treatment of immunological diseases. Its operations are entirely dependent on external funding. This chart shows how its financial structure, typically with minimal debt, reflects the high risk nature of its research programs and its reliance on equity capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Revelation Biosciences
Indaptus Therapeutics develops innovative immunotherapy methods. Like other companies in this field, its path to success lies through expensive trials. This chart shows the proportion of its survival and research financed by debt, a direct indicator of financial risk for investors.
Market segment debt to market segment book capitalization - Pharma immune
Revelation Biosciences is an early-stage biotech company focused on developing therapeutic and prophylactic treatments for respiratory viral infections. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company funds its research and development.
Debt to book value of all companies in the market
Revelation Biosciences is a biopharmaceutical company developing immune system drugs. Development in this area requires significant investment and is associated with high risks. This chart of total market debt provides an indication of the overall availability of capital, a key factor in funding clinical programs for such companies.
P/E of the company, segment and market as a whole
P/E - Revelation Biosciences
For Revelation Biosciences, a biopharmaceutical company, the P/E ratio is irrelevant. The company doesn't have a stable profit margin. Any values on this chart are random. Investors evaluate the company solely on the potential of its pipeline and the likelihood of success in clinical trials.
P/E of the market segment - Pharma immune
Revelation Biosciences is a biopharmaceutical company developing phosphorylated hexaacyl disaccharide (PHAD)-based drugs for the prevention and treatment of respiratory viral infections such as influenza. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors value innovative approaches to immune defense.
P/E of the market as a whole
Revelation Biosciences is a clinical-stage biopharmaceutical company developing drugs for the prevention and treatment of viral respiratory diseases. The company focuses on stimulating innate immunity. This risk appetite chart helps understand how investors evaluate new approaches to combating infectious diseases.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Revelation Biosciences
Revelation Biosciences is a biopharmaceutical company developing drugs for the prevention and treatment of immune-related diseases. This graph reflects market expectations for the success of its clinical programs. Future revenue depends on the results of trials and the commercial potential of its developments.
%20P%2FE%20Revelation%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Revelation-Biosciences&v=1772641606320 "Chart of the company's future (projected) P/E Revelation Biosciences")
Future (projected) P/E of the market segment - Pharma immune
Revelation Biosciences is an early-stage biotech company researching drugs to treat immune diseases. This chart is a measure of speculative hopes. It shows how the market evaluates the scientific concept and the potential of its developments compared to hundreds of other immunology startups vying for funding and success.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772641606348 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Revelation Biosciences is a clinical-stage biopharmaceutical company developing treatments and prevention methods for viral respiratory diseases. For companies like this, access to capital is vital. This chart, reflecting overall market sentiment, reflects investor willingness to finance long-term, risky healthcare projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772641606355 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Revelation Biosciences
Revelation Biosciences is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment and prevention of viral respiratory diseases. Its financial health is determined by R&D expenditures. This chart shows the R&D investments required to advance products through clinical trials to combat infectious diseases.
Profit of companies in the market segment - Pharma immune
Revelation Biosciences develops therapeutic and diagnostic products for the prevention and treatment of respiratory viral infections. This chart, which reflects overall profitability in the pharmaceutical sector, highlights the importance of pandemic preparedness. Revelation's success in developing comprehensive antiviral solutions could have a significant impact on the entire industry.
Overall market profit
Revelation Biosciences is a biotech company developing immune system drugs. Its valuation, like many companies in this sector, is speculative and based on expectations of future clinical data. Its story unfolds in the world of science, away from the economic cycles that impact traditional corporate earnings.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Revelation Biosciences
Revelation Biosciences is a biopharmaceutical company developing drugs for the prevention and treatment of respiratory viral infections. The future profit projections you see are speculative and depend entirely on the success of clinical trials of its nasal spray and other developments.
%20profit%20of%20the%20company%20Revelation%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Revelation-Biosciences&v=1772641606488 "Graph of future (projected) profit of the company Revelation Biosciences")
Future (predicted) profit of companies in the market segment - Pharma immune
Revelation Biosciences develops preventative and therapeutic drugs for the treatment of respiratory viral infections. This chart shows revenue forecasts for the entire immunological pharmaceuticals segment. It allows one to assess how the company's approach to disease prevention compares to overall expectations for the antiviral and immunomodulatory market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772641606540 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Revelation Biosciences is an early-stage biotech company working in the field of immunology. Its future depends entirely on successful R&D. This chart is important as an indicator of market sentiment. During periods of economic optimism, venture capital and public investors are more willing to fund long-term, risky scientific projects like Revelation's.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772641606559 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Revelation Biosciences
Revelation Biosciences is an early-stage biotech developing drugs for the prevention and treatment of respiratory viral infections. This chart, plotting market cap against minimum revenue, reflects its net potential. It shows how highly investors value its scientific approach in anticipation of future clinical success.
P/S market segment - Pharma immune
Revelation Biosciences is a biotechnology company developing therapeutic and preventative drugs based on its immunology platform. The company focuses on the treatment and prevention of viral infections. This chart shows investor estimates of revenue in the immunotherapy sector, demonstrating the level of expectations for Revelation's scientific platform and clinical development.
P/S of the market as a whole
Revelation Biosciences is a clinical-stage biopharmaceutical company developing treatments and prevention methods for viral respiratory diseases. Its valuation depends on the success of its clinical trials. This chart, showing the average valuation, highlights how high investor expectations for the biotech are compared to its current financial results.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Revelation Biosciences
Revelation Biosciences is a clinical-stage biotech company developing immune system drugs. This chart shows investor estimates of its potential future revenue. It reflects the market's confidence in the success of its scientific developments and the future commercial potential of its therapeutic candidates.
%20P%2FS%20Revelation%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Revelation-Biosciences&v=1772641606659 "The graph of the company's future (projected) P/S Revelation Biosciences")
Future (projected) P/S of the market segment - Pharma immune
Revelation Biosciences is a clinical-stage biopharmaceutical company developing drugs for the prevention and treatment of viral infections. The chart shows the average estimated future sales in the immunology sector. It helps understand how investors view Revelation's research and development potential compared to other approaches to combating infectious diseases.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772641606675 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Revelation Biosciences (REVB) is a biotech company developing drugs to prevent and treat respiratory viral infections. Their future depends on the results of clinical trials. This chart of overall economic sentiment is irrelevant for a company whose goal is to combat infectious diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772641606754 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Revelation Biosciences
Revelation Biosciences is a clinical-stage biotech company. Its revenue at this stage is generated not from product sales, but from strategic partnerships and grants. This chart reflects funding received for immunology research and development, confirming interest in its scientific approaches for disease prevention and treatment.
Sales of companies in the market segment - Pharma immune
Revelation Biosciences is a clinical-stage biopharmaceutical company developing drugs for the prevention and treatment of diseases. Its future revenue will depend on the success of its candidates in immunology and respiratory diseases, which is typical for a company whose value is based on scientific potential.
Overall market sales
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on immunology. Its value is driven by scientific developments, not current sales. However, the overall economic environment, reflected in this chart, influences investor sentiment and the availability of capital to fund the lengthy and expensive clinical trials necessary for success.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Revelation Biosciences
Revelation Biosciences is a clinical-stage biopharmaceutical company developing treatments and preventative measures for respiratory viral infections. Future revenue is entirely dependent on the success of its clinical programs. This chart reflects analysts' long-term expectations for the potential of its drugs in the large cold and flu market.
%20sales%20of%20the%20company%20Revelation%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Revelation-Biosciences&v=1772641606874 "Schedule of future (projected) sales of the company Revelation Biosciences")
Future (projected) sales of companies in the market segment - Pharma immune
Revelation Biosciences develops drugs for the prevention and treatment of diseases related to the immune system and inflammation. This chart shows the outlook for the immunology segment of the pharmaceutical industry. It reflects the high scientific interest in immunology, creating opportunities for Revelation's research and partnerships.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772641606898 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
This chart, reflecting the investment climate in biotechnology, is important for Revelation Biosciences. The company develops drugs for the prevention and treatment of respiratory viral infections. Funding for its research depends on capital inflows into the sector, which correlates with overall economic expectations.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772641606921 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Revelation Biosciences
Revelation Biosciences is a clinical-stage biotechnology company focused on developing drugs for the treatment and prevention of viral respiratory diseases. This chart reflects its investment in research. Future profitability depends on the success of clinical trials and the commercialization of its immune system products.
Market segment marginality - Pharma immune
Revelation Biosciences is a biopharmaceutical company developing drugs for the prevention and treatment of viral respiratory diseases. Its future profitability depends on the success of its clinical trial programs. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential and risks associated with Revelation's developments.
Market marginality as a whole
Revelation Biosciences is a clinical-stage biopharmaceutical company developing immune system drugs. Its development is entirely dependent on research results and access to funding. This chart reflects the overall investor appetite for risk, which is critical for biotech companies requiring capital to conduct costly clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Revelation Biosciences
Revelation Biosciences is a clinical-stage biopharmaceutical company focused on immunology. This graph shows a compact team of scientists and developers. A small staff is typical for R&D companies, where scientific expertise plays a key role. Changes in the graph may reflect progress or a change in focus in clinical programs.
Share of the company's employees Revelation Biosciences within the market segment - Pharma immune
Revelation Biosciences develops drugs to prevent and treat respiratory viral infections, including influenza. Its team of scientists is working on stimulating innate immunity. This chart shows the company's share of the total number of researchers in the field of immunology, reflecting its innovative approach to combating common diseases.
Number of employees in the market segment - Pharma immune
Revelation Biosciences is a biopharmaceutical company developing drugs for the prevention and treatment of diseases related to the immune system. This chart, reflecting employment in the immunology research sector, is important. The growing number of immunology researchers indicates an intensive search for new approaches to modulating the immune response, which is the core of Revelation's work.
Number of employees in the market as a whole
Revelation Biosciences is developing drugs to prevent and treat respiratory viral infections. This overall employment chart reflects society's ability to invest in preventative medicine. A stable economy and growing employment enable companies and governments to better care for public health, creating demand for innovative solutions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Revelation Biosciences (REVB)
Revelation Biosciences is a biotech company focused on immunology and developing treatments for respiratory diseases. This chart is a classic example of the R&D business. A company's value is determined not by its headcount, but solely by the value of its intellectual property—patents on potential drugs. The market values science, not labor.
%20of%20the%20company%20Revelation%20Biosciences%20(REVB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Revelation-Biosciences-REVB&v=1772641607171 "Chart of market capitalization per employee (in thousands of dollars) of the company Revelation Biosciences (REVB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Revelation Biosciences develops immune therapies. It's a science-intensive business, where market capitalization reflects the potential of the molecules being researched, not the size of the team. This chart allows investors to understand how highly the market values the intellectual work of each employee in the biotech sector, where a breakthrough idea can be worth billions.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772641607183 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Revelation Biosciences is a biotech company developing drugs to prevent and treat diseases related to the immune system. Its market capitalization is based on the potential of its scientific programs. This metric reflects a high cost per employee, typical for early-stage biotech, where investors value science over current sales.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772641607199 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Revelation Biosciences (REVB)
Revelation Biosciences is an early-stage biotech company. They research immune mechanisms for treating and preventing diseases. It's pure science. This chart reflects the company's "burn rate": it shows how much the company invests (negative return) per scientist to test early hypotheses in the lab.
%20Chart%20Revelation%20Biosciences%20(REVB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Revelation-Biosciences-REVB&v=1772641607216 "Company Profit Per Employee (in thousands of dollars) Chart Revelation Biosciences (REVB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Revelation Biosciences develops drugs for the prevention and treatment of respiratory viral infections. For an early-stage biotech company, this metric is often negative due to high R&D costs. The graph is important for assessing cost trends and the potential for future profits should the product successfully complete clinical trials and reach the market.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772641607232 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Revelation Biosciences (REVB) is a clinical-stage biotechnology company developing drugs for the prevention and treatment of respiratory viral infections (e.g., influenza). It is an R&D company and has no profit. This metric is negative and represents the "cost" of a single scientist working on a potential preventative treatment.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772641607237 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Revelation Biosciences (REVB)
Revelation Biosciences is a clinical-stage biopharmaceutical company focused on immunology. At this stage, revenue may be nonexistent. This chart is important for assessing future potential: a single successful drug could lead to a multifold increase in revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Revelation-Biosciences-REVB&v=1772641607247 "Sales chart per company employee Revelation Biosciences (REVB)")
Sales per employee in the market segment - Pharma immune
Revelation Biosciences is a clinical-stage biotech company focused on immunology (for example, for the treatment of allergic rhinitis). It's a pure R&D company with no commercial products. This graph shows that the productivity of their research team isn't measured in sales. Their goal is to bring drugs to successful clinical trials.
Sales per employee for the market as a whole
Tuya (TUYA) is a global IoT platform that enables manufacturers to quickly make their products "smart" (e.g., light bulbs, sockets). They provide the chips, software, and cloud. This chart demonstrates the power of the platform business model. Tuya doesn't manufacture the devices themselves, but sells scalable technology. Revenue grows with each new partner connecting to their cloud.
Short shares by company, segment and market as a whole
Shares shorted by company Revelation Biosciences (REVB)
Revelation Biosciences (REVB) is a clinical-stage biotech. This chart tracks short positions. The bears are betting that the company is burning through cash, and that its immunology and infection treatment projects are unlikely to prove effective in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Revelation-Biosciences-REVB&v=1772641607274 "Short Shares Chart for the Company Revelation Biosciences (REVB)")
Shares shorted by market segment - Pharma immune
Revelation Biosciences (REVB) develops intranasal drugs for the treatment of respiratory diseases and allergies. The chart below shows the overall short position in the biotech sector. It demonstrates the general investor skepticism regarding the success of risky clinical trials, especially in the early stages.
Shares shorted by the overall market
Revelation Biosciences is an early-stage biotech focused on immunology. This chart illustrates the overall market pessimism. When fear reigns, investors are reluctant to finance a cash burn. They sell off shares of pre-profitable companies like REVB, preferring to cash out until the market calms down, without waiting for news about trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Revelation Biosciences (REVB)
This oscillator for Revelation Biosciences is a barometer of biotech speculation. The company is in the early stages, developing drugs to treat infections and allergies. "Overheating" (above 70) occurs on announcements of trial launches. A key trial failure (as with COVID) or a lack of cash leads to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Revelation-Biosciences-REVB&v=1772641607528 "RSI 14 indicator chart for the company's stock Revelation Biosciences (REVB)")
RSI 14 Market Segment - Pharma immune
Revelation Biosciences is an early-stage biopharmaceutical company developing drugs to prevent and treat infections (such as influenza) by stimulating the innate immune system. This chart reflects the overall sentiment in the biotech sector and helps assess how the market views this speculative industry.
RSI 14 for the overall market
Revelation Biosciences (REVB) is a biotech company developing immune system drugs. Like many early-stage companies, it relies on research funding. This chart shows the overall market "temperature." During periods of euphoria (overbought), investors are willing to take risks, investing in promising but unproven technologies. During periods of panic (oversold), capital for REVB dries up.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast REVB (Revelation Biosciences)
Revelation Biosciences is a biotech company focused on developing drugs to treat allergic and respiratory diseases (e.g., an intranasal spray). This chart shows the speculative average 12-month price target from analysts, which is almost entirely based on their assessment of the company's R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-REVB-Revelation-Biosciences&v=1772641607644 "A chart showing analyst consensus forecasts for the expected stock price. REVB (Revelation Biosciences)")
The difference between the consensus estimate and the actual stock price REVB (Revelation Biosciences)
Revelation Biosciences is a biotech company developing drugs (nasal sprays) to "train" the innate immune system to fight viruses (flu). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their view of this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-REVB-Revelation-Biosciences&v=1772641607746 "A chart showing the difference between the consensus forecast and the actual stock price. REVB (Revelation Biosciences)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Revelation Bio is an R&D biotech company developing drugs for the treatment of inflammatory and infectious diseases. This is high-risk R&D. This chart reflects analysts' overall expectations for the entire immune pharma sector. It shows how confident experts are in the success of junior biotechs in this field.
Analysts' consensus forecast for the overall market share price
Revelation Biosciences is a biotech company specializing in developing immune system drugs (e.g., to treat infections). This chart shows the overall market "risk appetite." For REVB, a clinical-stage company, overall market optimism (the rising chart) is critical for raising capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Revelation Biosciences
Revelation Biosciences is an immune biotech company. Their specialty is the R&D of anti-inflammatory drugs (based on HEC) for the treatment of chronic diseases (such as kidney disease) and viral diseases (COVID). This chart is a pure indicator of their R&D. It doesn't reflect revenue, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Pharma immune
Revelation Biosciences is a biopharmaceutical company focused on prevention and treatment. Their lead candidate is an intranasal spray designed to train the innate immune system to fight infections. This chart compares their composite index to the sector, showing how this preventative strategy compares to others.
The AKIM Index for the overall market
Revelation Biosciences is a biopharmaceutical company developing immunological drugs for the treatment and prevention of diseases (kidney, infections). This chart, reflecting the market average, provides a macro backdrop. It helps assess how REVB, its early scientific history, compares to overall economic trends.
